Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 4,701–4,800 of 15,747
SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease
Luxenburger, H., & Thimme, R. (2023) · Gut · doi:10.1136/gutjnl-2023-329623 · Cited by 20
Brockman, M. A., Mwimanzi, F. M., Sang, Y., Ng, K., Agafitei, O., Ennis, S., Lapointe, H. R., Young, L., Umviligihozo, G., Burns, L., et al. (2021) · medRxiv · doi:10.1101/2021.03.17.21253773 · Cited by 20
The Effect of Cholesterol Content on the Adjuvant Activity of Nucleic-Acid-Free Lipid Nanoparticles
Anindita, J., Tanaka, H., Yamakawa, T., Sato, Y., Matsumoto, C., Ishizaki, K., Oyama, T., Suzuki, S., Ueda, K., Higashi, K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020181 · Cited by 22
“The outbreak was controlled by the development of LNP-based RNA vaccines by Moderna (Spikevax ® ) [20,21] and Pfizer/BioNTech (Comirnaty ® ) [22,23].”
MethodCovid-19 vaccination and pregnancy: a systematic review of maternal and neonatal outcomes
Kontovazainitis, C.-G., Katsaras, G. Ν., Gialamprinou, D., & Mitsiakos, G. (2023) · Journal of Perinatal Medicine · doi:10.1515/jpm-2022-0463 · Cited by 29
“trials, but no trial initially included pregnant and/or lactating women [12, 17].”
BackgroundNiederkofler, S., Parkkila, P., Aliakbarinodehi, N., Sasanian, N., Emilsson, G., Ulkoski, D., Ferreira, C. J. O., Galenkamp, N. S., Silva, B. F. B., Lundberg, D., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c17052 · Cited by 26
Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine
Ndzouboukou, J. B., Zhang, Y., Lei, Q., Lin, X., Yao, Z., Fu, H., Yuan, L., & Fan, X. (2021) · Current Medical Science · doi:10.1007/s11596-021-2461-8 · Cited by 22
Paul, É., Brown, G. W., Kalk, A., & Ridde, V. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.045 · Cited by 24
“This gives the world hope that the pandemic can ultimately be controlled.”
de Moura, I. A., Silva, A. J. D., de Macêdo, L. S., Invenção, M. D. C. V., de Sousa, M. M. G., & de Freitas, A. C. (2022) · Pathogens · doi:10.3390/pathogens11121444 · Cited by 21
New-Onset Acute Kidney Disease Post COVID-19 Vaccination
Li, Y., Rao, M., & Xu, G. (2022) · Vaccines · doi:10.3390/vaccines10050742 · Cited by 21
“Once injected, the mRNA is translated into the target protein in vivo, resulting in a strong immune response, and a 2-dose regimen confers 95% protection against COVID-19 [5].”
BackgroundThe effect of HIV on COVID-19 vaccine responses
Levy, I., & Rahav, G. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000790 · Cited by 23
Spokeviciute, B., Kholia, S., & Brizzi, M. F. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107352 · Cited by 23
Meta-analysis and comprehensive study of coronavirus outbreaks: SARS, MERS and COVID-19
Berber, E., Sumbria, D., & Çanakoğlu, N. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.06.007 · Cited by 22
“Frontrunners of these types of vaccines are NT162b2 (Pfizer-BioNTech; Germany and USA collaboration) and RNA-1273 (Moderna, USA) and phase trial results indicated that verall, seroconversion results reached more than 90% among the accinated human subjects [69,70].”
BackgroundPredictors of Real-World Parents’ Acceptance to Vaccinate Their Children Against the COVID-19
Galanis, P., Vraka, I. S., Siskou, O. C., Konstantakopoulou, O., Katsiroumpa, A., Moisoglou, I., & Καϊτελίδου, Δ. (2022) · Acta medica Lituanica · doi:10.15388/amed.2021.29.1.4 · Cited by 24
Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis
Chen, L., Cai, X., Zhao, T., Han, B., Xie, M., Cui, J., Zhang, J., Wang, C., Liu, B., Lu, Q., et al. (2022) · Vaccines · doi:10.3390/vaccines10040596 · Cited by 21
“[43] RCT Argentina, Brazil, South Africa, etc.”
Fernandes, A., Chaudhari, S., Jamil, N., & Gopalakrishnan, G. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.01.013 · Cited by 22
Abu‐Rumeileh, S., Mayer, B., Still, V., Tumani, H., Otto, M., & Şenel, M. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10849-3 · Cited by 20
Nocebo affects after COVID-19 vaccination
Sever, P. S. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100273 · Cited by 19
“Of 171 studies, 3 were finally selected as meeting the inclusion criteria for the survey, [5,6,7] thereby potentially introducing bias.”
Lassaunière, R., Polacek, C., Fonager, J., Bennedbæk, M., Boding, L., Rasmussen, M., & Fomsgaard, A. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.49.2101059 · Cited by 20
Nicolas, A., Sannier, G., Dubé, M., Nayrac, M., Tauzin, A., Painter, M. M., Goel, R. R., Laporte, M., Gendron‐Lepage, G., Medjahed, H., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105904 · Cited by 23
Li, G., Gerlovin, H., Muñiz, M. J. F., Wise, J. K., Madenci, A. L., Robins, J. M., Aslan, M., Cho, K., Gaziano, J. M., Lipsitch, M., et al. (2023) · Epidemiology · doi:10.1097/ede.0000000000001709 · Cited by 25
Four cases of audio-vestibular disorders related to immunisation with SARS-CoV-2 mRNA vaccines
Ekobena, P., Rothuizen, L. E., Bedussi, F., Guilcher, P., Meylan, S., Ceschi, A., Girardin, F., & Dao, K. (2022) · International Journal of Audiology · doi:10.1080/14992027.2022.2056721 · Cited by 23
“The efficacy and safety data reported from Phase 2 or 3 trials were promising for both of these vaccines (Polack et al. 2020; Baden et al. 2021).”
Background“Let me choose my COVID-19 vaccine”
Dal‐Ré, R., Stephens, R., & Sreeharan, N. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.01.030 · Cited by 20
Khawaja, F., Papanicolaou, G. A., Dadwal, S., Pergam, S. A., Wingard, J. R., Boghdadly, Z. E., Abidi, M. Z., Waghmare, A., Shahid, Z., Michaels, L., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.10.010 · Cited by 24
“have shown in large phase III clinical trials involving immunocompetent subjects to be more than 90% effective at preventing laboratory-confirmed, symptomatic, and severe COVID-19 [7,8].”
BackgroundMethodInfluentialCocooning against COVID‐19: The argument for vaccinating caregivers of patients with cancer
Woodfield, M. C., Pergam, S. A., & Shah, P. D. (2021) · Cancer · doi:10.1002/cncr.33598 · Cited by 20
Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine
(2022) · doi:10.1101/2022.12.17.22283625 · Cited by 20
“When the original Coronavirus Disease 2019 (COVID-19) vaccines first became available in 2020, there was ample evidence of efficacy from randomized clinical trials [1,2].”
BackgroundSide Effects of the COVID-19 Vaccines
Dumitru, I. M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105668 · Cited by 20
Wan, E., Mok, A., Yan, V. K. C., Chan, C. I. Y., Wang, B., Lai, F., Chui, C., Li, X., Wong, C., Lau, C., et al. (2022) · Journal of Travel Medicine · doi:10.1093/jtm/taac119 · Cited by 19
“CoronaVac 28,70 4 (16) 94,500 (13) 5,277 (22) 40,150 (17) 263 (22) 1,953 (17) 1,411 (19) 13,67 5 (19)”
Circular RNA lipid nanoparticle vaccine against SARS-CoV-2
Swingle, K. L., Hamilton, A. G., Han, X., Liao, K., Safford, H. C., Thatte, A. S., Geisler, H. C., Xu, J., Saw, T. Y., Wan, Y., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2505718122 · Cited by 28
Higashimoto, Y., Kozawa, K., Miura, H., Kawamura, Y., Ihira, M., Hiramatsu, H., Suzuki, R., Haga, K., Takai-Todaka, R., Sawada, A., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2105611 · Cited by 21
Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13818 · Cited by 18
Synthetic RNA-based post-transcriptional expression control methods and genetic circuits
Pardi, M. L., Wu, J., Kawasaki, S., & Saito, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114196 · Cited by 21
Melton, A., Doyle‐Meyers, L. A., Blair, R. V., Midkiff, C. C., Melton, H. J., Russell‐Lodrigue, K., Aye, P. P., Schiro, F. R., Fahlberg, M. D., Szeltner, D. M., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010162 · Cited by 21
Català, M., Li, X., Prats, C., & Prieto‐Alhambra, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-98216-0 · Cited by 20
Immune gene expression analysis indicates the potential of a self-amplifying Covid-19 mRNA vaccine
Ong, E. Z., Yee, J. X., Ooi, J. S. G., Syenina, A., de Alwis, R., Chen, S., Sim, J. X. Y., Kalimuddin, S., Leong, Y. S., Chan, Y. F. Z., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00573-y · Cited by 21
Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice
Lu, C., Li, Y., Chen, R., Hu, X., Leng, Q., Song, X., Lin, X., Ye, J., Wang, J., Li, J., et al. (2024) · Viruses · doi:10.3390/v16020211 · Cited by 20
“In the early days of the COVID-19 outbreak, two mRNA vaccines of the novel coro-navirus achieved great success, so mRNA vaccine technology has received widespread attention [16,17].”
BackgroundDissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell immunoprofiling
Schreibing, F., Hannani, M. T., Kim, H., Nagai, J. S., Ticconi, F., Fewings, E., Bleckwehl, T., Begemann, M., Torow, N., Kuppe, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1066176 · Cited by 24
“However, despite vaccine efficacy, particularly in preventing severe COVID-19 (3, 4), breakthrough infections occur repeatedly (5) and can result in severe disease (6–8) as well as serious long-term health consequences (9).”
BackgroundGao, Y., Wang, W., Yang, Y., Zhao, Q., Yang, C., Jia, X., Liu, Y., Zhou, M., Zeng, W., Huang, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202204598 · Cited by 25
Li, R., Li, Y., Zou, Z., Liu, Y., Li, X., Zhuang, G., Shen, M., & Zhang, L. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2021.801763 · Cited by 22
HAJDUCZOK, A. G., DiJoseph, K., Bent, B., Thorp, A., Mullholand, J. B., MacKay, S. A., Barik, S., Coleman, J., Paules, C. I., & Tinsley, A. (2021) · JMIR Formative Research · doi:10.2196/28568 · Cited by 22
Arroliga, M. E., Dhanani, K., Arroliga, A. C., Huddleston, P. S., Trahan, J., Aguilar, T., & Weldon, D. (2021) · Allergy and Asthma Proceedings · doi:10.2500/aap.2021.42.210069 · Cited by 20
Vulpis, E., Giulimondi, F., Digiacomo, L., Zingoni, A., Safavi‐Sohi, R., Sharifi, S., Caracciolo, G., & Mahmoudi, M. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00291 · Cited by 22
Understanding T cell aging to improve anti-viral immunity
Zhang, H., Weyand, C. M., Goronzy, J. J., & Gustafson, C. E. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.09.017 · Cited by 20
Infection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting
Townsend, J. P., Hassler, H. B., & Dornburg, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28461 · Cited by 25
Butt, A. A., Talisa, V. B., Peng, Y., Shaikh, O. S., Omer, S. B., & Mayr, F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac178 · Cited by 21
COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities
Manansala, M., Chopra, A., Baughman, R. P., Novak, R. M., Lower, E. E., Culver, D. A., Korsten, P., Drake, W. P., Judson, M. A., & Sweiss, N. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.672028 · Cited by 21
“1% for Pfizer and Moderna vaccines, respectively) (29, 30).”
BackgroundTrakarnvanich, T., Ngamvichchukorn, T., Phumisantiphong, U., Pholtawornkulchai, K., Phochanasomboon, K., & Manomaipiboon, A. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.067 · Cited by 21
Spiliopoulou, P., van Rensburg, H. J. J., Avery, L. M., Kulasingam, V., Razak, A. R. A., Bedard, P. L., Hansen, A. R., Chruscinski, A. J., Wang, B., Kulikova, M., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-022-05548-4 · Cited by 23
“The development of vaccines preventing severe disease, hospitalization and death from COVID-19 has marked a significant achievement [5, 6].”
BackgroundLarge-vessel vasculitis following the Pfizer-BioNTech COVID-19 vaccine
Gilio, M., & Stefano, G. D. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02908-4 · Cited by 20
“Physicians should be aware of this complication, but should continue to encourage vaccination efforts given the well documented safety profile and efficacy of the Pfizer-BioNTech BNT16B2b2 mRNA vaccine [5].”
BackgroundWhat Lessons can Be Learned From the Management of the COVID-19 Pandemic?
Quinn, G. A., Connolly, R., ÓhAiseadha, C. O., Hynds, P. D., Bagus, P., Brown, R. B., Cáceres, C. F., Craig, C. E. H., Connolly, M., Domingo, J. L., et al. (2025) · International Journal of Public Health · doi:10.3389/ijph.2025.1607727 · Cited by 27
Tober‐Lau, P., Schwarz, T., Hillus, D., Spieckermann, J., Helbig, E. T., Lippert, L. J., Thibeault, C., Koch, W., Bergfeld, L., Niemeyer, D., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2708.210887 · Cited by 20
Hansen, C. B., Jarlhelt, I., Hasselbalch, R. B., Hamm, S. R., Fogh, K., Pries‐Heje, M. M., Møller, D. L., Heftdal, L. D., Pérez‐Alós, L., Sørensen, E., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13366 · Cited by 20
Lasagna, A., Lilleri, D., Agustoni, F., Percivalle, E., Borgetto, S., Alessio, N., Comolli, G., Sarasini, A., Bergami, F., Sammartino, J. C., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100359 · Cited by 21
Bibliometric and visual analysis of vaccination hesitancy research from 2013 to 2022
Chen, C., Yang, Q., Tian, H., Wu, J., Chen, L., Ji, Z., Zheng, D., Chen, Y., Li, Z., & Lu, H. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2226584 · Cited by 23
HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development
Shepherd, B. L. O., Chang, D., Vasan, S., Ake, J. A., & Modjarrad, K. (2022) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00597-4 · Cited by 21
“As such, two highly effective mRNA vaccines have now received either FDA emergency authorization or full approval [9, 10].”
BackgroundStroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study
López-Mena, D., García-Grimshaw, M., Saldivar-Dávila, S., Hernandez-Vanegas, L. E., Saniger-Alba, M. D. M., Gutiérrez, A., Carrillo-Mezo, R., Valdez-Ruvalcaba, H. E., Cano-Nigenda, V., Flores-Silva, F. D., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200388 · Cited by 23
“Serious AEFIs are those presenting with any clinical manifestation meeting 1 or more of the following criteria: (1) put life in imminent danger, (2) require or prolong in-hospital treatment, (3) lead to persistent or significant disability, (4) lead to death, or (5) in the case of pregnant women, cause in utero malfor…”
BackgroundBNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity
Vizcarra, P., Häemmerle, J., Velasco, H., Velasco, T., Fernández-Escribano, M., Vallejo, A., & Casado, J. L. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.074 · Cited by 20
“These observations are consistent with the results of phase 3 clinical trials and nationwide surveillance reports [1,4].”
InfluentialBroadly neutralizing antibodies targeting HIV: Progress and challenges
Nandagopal, P., Khan, A., & Lawson, B. R. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109809 · Cited by 24
Affeldt, P., Koehler, F. C., Brensing, K. A., Adam, V., Burian, J., Butt, L., Gies, M., Grundmann, F., Hinrichs, S., Johannis, W., et al. (2021) · Microorganisms · doi:10.3390/microorganisms10010004 · Cited by 22
Tu, W., Zhang, P., Roberts, A., Allen, K. S., Williams, J. L., Embí, P. J., & Grannis, S. J. (2022) · American Journal of Public Health · doi:10.2105/ajph.2022.307112 · Cited by 23
Giambra, V., Piazzolla, V., Cocomazzi, G., Squillante, M. M., Santis, E. D., Totti, B., Cavorsi, C., Giuliani, F., Serra, N., & Mangia, A. (2022) · Vaccines · doi:10.3390/vaccines10081281 · Cited by 20
“Two mRNA-based technology vaccines, BNT162b2 and mRNA-1273, were developed by Pfizer-BioNTech and Moderna, respectively [1,2]; both were shown to be efficient in protecting against SARS-CoV-2 related disease [1,2].”
BackgroundMethodAlam, M. S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13285 · Cited by 25
Wing, S. L., Thomas, D., Balamchi, S., Ip, J., Naylor, K. L., Dixon, S. N., McArthur, E., Kwong, J. C., Perl, J. M., Atiquzzaman, M., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000108 · Cited by 21
Ramirez, G. A., Della‐Torre, E., Moroni, L., Yacoub, M., & Dagna, L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220539 · Cited by 20
Cao, H., Yang, S., Wang, Y., Luan, N., Yin, X., Lin, K., & Liu, C. (2021) · Vaccines · doi:10.3390/vaccines9111261 · Cited by 20
Harmon, M., & Lau, J. (2021) · Indoor and Built Environment · doi:10.1177/1420326x211039544 · Cited by 22
Younis, M. A., Sato, Y., Kimura, S., & Harashima, H. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00079c · Cited by 26
Bogaert, B., Debisschop, A., Ehouarne, T., Eeckhoutte, H. P. V., Volder, J. D., Jacobs, A., Pottie, E., Rycke, R. M. D., Crabbé, A., Mestdagh, P., et al. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c03345 · Cited by 22
Nordström, P., Ballin, M., & Nordström, A. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5814 · Cited by 22
Gralnek, I. M., Hassan, C., Ebigbo, A., Fuchs, A., Beilenhoff, U., Antonelli, G., Bisschops, R., Arvanitakis, M., Bhandari, P., Bretthauer, M., et al. (2021) · Endoscopy · doi:10.1055/a-1700-4897 · Cited by 24
Polymeric nanocarriers for therapeutic gene delivery
Zhang, J., Yang, X., Chang, Z., Zhu, W., Ma, Y., & He, H. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101015 · Cited by 51
Pepperrell, T., Rodgers, F., Tandon, P., Sarsfield, K., Pugh-Jones, M., Rashid, T., & Keestra, S. (2021) · Global Health Action · doi:10.1080/16549716.2021.1892309 · Cited by 20
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
Usdan, L. S., Patel, S., Rodriguez, H., Xu, X., Lee, D.-Y., Finn, D., Wyper, H., Lowry, F. S., Mensa, F., Lu, C., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad718 · Cited by 20
“BA.1-adapted vaccines, the latter of which was authorized in some jurisdictions [3, 15, 26, 28, 32].”
BackgroundSelf-citationYu, X., Xu, T., Shi, H., Hong, J., Jin, X., Cao, L., Wang, J., Lin, Y., Pan, Z., Wang, S., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.142841 · Cited by 20
Parés‐Badell, O., Martínez‐Gómez, X., Pinós, L., Borràs-Bermejo, B., Uriona, S., Otero‐Romero, S., Rodrigo‐Pendás, J. Á., Cossio‐Gil, Y., Agustí, A., Aguilera, C., et al. (2021) · Vaccines · doi:10.3390/vaccines9121463 · Cited by 22
“Both vaccines were shown in clinical trials [5,7] to be very effective at preventing severe disease and hospitalization and to have favorable safety profiles.”
BackgroundResultInfluentialTamming, L. A., Duque, D., Tran, A., Zhang, W., Pfeifle, A., Laryea, E., Wu, J., Raman, S. N. T., Gravel, C., Russell, M. S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.785349 · Cited by 22
“Two mRNA vaccines in particular, Moderna’s mRNA-1273 (Spikevax) (3, 4) and Pfizer/BioNTech ’s BNT162b2 (Comirnaty) (5, 6) have proven to be extremely safe and effective at preventing COVID-19 illness.”
BackgroundMarks, K., & Gulick, R. M. (2023) · Annals of Internal Medicine · doi:10.7326/aitc202310170 · Cited by 23
Nucleocapsid Specific Diagnostics for the Detection of Divergent SARS-CoV-2 Variants
Isaacs, A., Amarilla, A. A., Aguado, J., Modhiran, N., Albornoz, E. A., Baradar, A. A., McMillan, C. L. D., Choo, J. J. Y., Idris, A., Supramaniam, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.926262 · Cited by 23
Magen, E., Mukherjee, S., Bhattacharya, M., Detroja, R., Merzon, E., Blum, I., Livoff, A., Shlapobersky, M., Baum, G., Talisman, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10071135 · Cited by 24
“In the clinical trials, participants reported short-term mild local adverse reactions, including injection site pain, swelling, fever, fatigue, myalgia, and lymphadenopathy [4].”
BackgroundChallenges and Opportunities for COVID-19 Vaccines in Patients with Cancer
Kuderer, N. M., Hill, J. A., Carpenter, P. A., & Lyman, G. H. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1885596 · Cited by 20
Valk, A. M., Keijser, J. B. D., van Dam, K. P. J., Stalman, E. W., Wieske, L., Steenhuis, M., Kummer, L. Y. L., Spuls, P. I., Bekkenk, M. W., Musters, A. H., et al. (2024) · Allergy · doi:10.1111/all.16089 · Cited by 20
Conticini, E., d’Alessandro, M., Grazzini, S., Fornaro, M., Sabella, D. V. A., Lopalco, G., Giardina, F., Colafrancesco, S., Rizzo, C., Guggino, G., et al. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-03028-3 · Cited by 21
“The use of recently developed mRNA vaccines, such as BNT162b2 (Pfizer) [1], and mRNA-1273 (Moderna) [2], and ChAdOx1-S (AstraZeneca) adenovirus vector vaccine [3], has provided effective protection against severe COVID-19.”
MethodTherapeutic vaccine for chronic diseases after the COVID-19 Era
Nakagami, H., Hayashi, H., Shimamura, M., Rakugi, H., & Morishita, R. (2021) · Hypertension Research · doi:10.1038/s41440-021-00677-3 · Cited by 24
Cutaneous adverse reactions following COVID‐19 vaccinations: A systematic review and meta‐analysis
Shafie’ei, M., Jamali, M., Akbari, Z., Sarvipour, N., Ahmadzade, M., & Ahramiyanpour, N. (2022) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.15261 · Cited by 19
Carvalho, K., Vicente, J. P., Jakovljević, M., & Teixeira, J. P. (2021) · Bioengineering · doi:10.3390/bioengineering8060084 · Cited by 22
Jeda, A. S., Abbassi, S., Mousavizadeh, A., Esghaie, M., Bokharaei‐Salim, F., Jeddi, F., Shafaati, M., & Abdoli, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108232 · Cited by 26
Antolí, A., Rocamora-Blanch, G., Framil, M., Mas-Bosch, V., Velázquez, S. N., Bermúdez, C., Martínez‐Yélamos, S., Dopico, E., Calatayud, L., Muñoz, N. G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.895209 · Cited by 22
“By the time this study was performed, four vaccines had already been approved by the European Medicines Agency (21) (two mRNA and two viral vector-based vaccines): BNT162b2 (Comirnaty®; BioNTech and Pfizer) (22, 23), mRNA-1273 (Spikevax®; Moderna) (24), ChAdOx1 nCoV-19 (Vaxzevria®; AstraZeneca) (25) and Ad26.”
BackgroundVaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cellsPreprint
Mishra, P. K., Bruiners, N., Ukey, R., Datta, P., Onyuka, A., Handler, D., Hussain, S., Honnen, W. J., Singh, S., Guerrini, V., et al. (2021) · medRxiv · doi:10.1101/2021.04.11.21255153 · Cited by 21
“Moreover, the ongoing SARS-CoV-2 vaccination campaign worldwide, including two mRNA vaccines [Moderna (mRNA-1273) or Pfizer–BioNTech (BNT162b2)] (9, 10), raises questions about the properties and duration of humoral and cellular responses to vaccination.”
BackgroundComprehensive evaluation of T7 promoter for enhanced yield and quality in mRNA production
Sari, Y., Rosa, S. S., Jeffries, J. W. E., & Marques, M. P. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-59978-5 · Cited by 29
Musafir, R. R., Suryanto, A., & Darti, İ. (2021) · Communication in Biomathematical Sciences · doi:10.5614/cbms.2021.4.2.3 · Cited by 20
“Several types of COVID-19 vaccines such as BioNTech, Moderna, Sinovac, and BNT162b2 mRNA have efficacy above 90% [23], [34].”
BackgroundAbdul‐Mutakabbir, J. C., Granillo, C., Peteet, B. J., Dubov, A., Montgomery, S., Hutchinson, J., Casey, S. J., Simmons, K., Fajardo, A., & Belliard, J. C. (2022) · Vaccines · doi:10.3390/vaccines10081364 · Cited by 20
Raja, A. S., Niforatos, J. D., Anaya, N., Graterol, J., & Rodriguez, R. M. (2021) · medRxiv · doi:10.1101/2021.02.28.21252610 · Cited by 21
Early approval of COVID-19 vaccines: Pros and cons
Rahman, M. A., & Islam, M. S. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1944742 · Cited by 25
“This was not only the first mRNA vaccine approved for human use but also the fastest formulated vaccine whose development was initiated just 11 months back on 10 January 2020.(34) One week later, the FDA issued an EUA for the another mRNA vaccine, named ‘mRNA-1273ʹ, also known as the ‘Moderna COVID-19 Vaccine.”
BackgroundInfluentialTwo Cases of Severe Autoimmune Thyrotoxicosis Following SARS-CoV-2 Infection
Edwards, K., & Hussain, I. (2021) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096211056497 · Cited by 21
Rahamimov, N., Baturov, V., Shani, A., Ben-Zoor, I., Fischer, D., & Chernihovski, A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.081 · Cited by 23
A 2-month field cohort study of SARS-CoV-2 in saliva of BNT162b2 vaccinated nursing home workers
Saegerman, C., Diep, A. N., Renault, V., Donneau, A., Stamatakis, L., Coppieters, W. R., Michel, F., Breuer, C., Dandoy, M., Ek, O., et al. (2022) · Communications Medicine · doi:10.1038/s43856-021-00067-3 · Cited by 22
VIRFIM: an AI and Internet of Medical Things-driven framework for healthcare using smart sensors
Khowaja, S. A., Khuwaja, P., Dev, K., & D’Aniello, G. (2021) · Neural Computing and Applications · doi:10.1007/s00521-021-06434-4 · Cited by 26
“Currently, there are a total of 5 vaccines that have entered phase 3 trails BBIBP-CorV (Sinopharm), Sinovac, Sputnik V from Gamaleya Research Institute, ChAd0 9 1 nCoV-19 from AstraZeneca and University of Oxford, mRNA-1273 from Moderna, and BNT162b2 from the Moderna as well [9].”
BackgroundInfluentialEffectiveness and Safety of COVID-19 Vaccinations: An Umbrella Meta-Analysis
Jiesisibieke, Z. L., Liu, W., Yang, Y., Chien, C.-W., & Tung, T. (2023) · International Journal of Public Health · doi:10.3389/ijph.2023.1605526 · Cited by 23
Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines
Borrajo, M. L., Lou, G., Anthiya, S., Lapuhs, P., Moreira, D., Tobío, A., Loza, M. I., Vidal, A., & Alonso, M. J. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01635-5 · Cited by 23
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.